We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




PET/ctDNA-Guided Approach Helps Determine Lymphoma Treatment

By MedImaging International staff writers
Posted on 26 Jun 2025
Image: Multitasking ctDNA can help guide lymphoma treatment (Photo courtesy of 123RF)
Image: Multitasking ctDNA can help guide lymphoma treatment (Photo courtesy of 123RF)

Currently, no diagnostic tests exist that can determine the genetic profile of a tumor in diffuse large B-cell lymphoma (DLBCL) before treatment, a critical factor for choosing the appropriate therapy. Now, new research indicates that circulating tumor DNA (ctDNA) is becoming a valuable tool in the initial treatment of DLBCL. Its emerging applications include identifying genetic subtypes and informing decisions on whether to intensify or reduce chemotherapy.

The findings, from the preliminary results of the phase 2 SAKK 38/19 trial presented by researchers from the Oncology Institute of Southern Switzerland (IOSI, Bellinzona, Switzerland), demonstrated that a PET/ctDNA-guided approach in frontline DLBCL is feasible in a multicenter setting. Patient stratification and therapy assignment based on combined PET and ctDNA outcomes were effectively implemented. The SAKK 38/19 trial aims to identify patients carrying the MCD genetic subtype—known for poor response to standard R-CHOP chemotherapy (rituximab + cyclophosphamide, doxorubicin hydrochloride [hydroxydaunomycin], vincristine [Oncovin], prednisone)—who might respond better when a Bruton tyrosine kinase inhibitor like acalabrutinib is added to the regimen.

The study, conducted across 16 locations in Switzerland and 3 in Italy, utilized ctDNA to pinpoint individuals with the MCD subtype by detecting the MYD88 and CD79B mutations associated with it. Out of 230 treatment-naive patients with CD20-positive DLBCL screened for participation, ctDNA was found in 194 patients (88.2%), and 35 (15.9%) carried one or both of the target mutations. Notably, the turnaround time for ctDNA genetic profiling in the 124 patients included in the full analysis set—after accounting for screening failures and other exclusions—was just 9 days, with the median time to treatment initiation recorded at 15 days.

“We have demonstrated that a PET/ctDNA-guided approach in frontline DLBCL is feasible in a multicenter setting,” said first author Anastasios Stathis, MD, of the IOSI, in presenting the findings at the 18th International Conference on Malignant Lymphoma (ICML) 2025. “The allocation of patients and treatment based on the combined results of PET and ctDNA is operationally successful.”

Related Links:
IOSI

Diagnostic Ultrasound System
DC-80A
Half Apron
Demi
Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
Mammography System (Analog)
MAM VENUS

Channels

Nuclear Medicine

view channel
Image: Perovskite crystal boules are grown in carefully controlled conditions from the melt (Photo courtesy of Mercouri Kanatzidis/Northwestern University)

New Camera Sees Inside Human Body for Enhanced Scanning and Diagnosis

Nuclear medicine scans like single-photon emission computed tomography (SPECT) allow doctors to observe heart function, track blood flow, and detect hidden diseases. However, current detectors are either... Read more

General/Advanced Imaging

view channel
Image: The Angio-CT solution integrates the latest advances in interventional imaging (Photo courtesy of Canon Medical)

Cutting-Edge Angio-CT Solution Offers New Therapeutic Possibilities

Maintaining accuracy and safety in interventional radiology is a constant challenge, especially as complex procedures require both high precision and efficiency. Traditional setups often involve multiple... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.